Oxford BioMedica plc Director's Share Purchase

RNS Number : 6765P
Oxford Biomedica PLC
09 June 2015







Oxford BioMedica plc Director's Share Purchase



Oxford, UK - 9 June 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 9 June 2015 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:







Interest after purchase

Director / PDMR


Price per share (p)

Number of Ordinary Shares acquired

Number of Ordinary Shares

% of total

issued share capital

Daniel Soland

Non-executive director






The issued share capital of the Group is 2,568,264,700 1p ordinary shares.


- Ends -


For further information, please contact:



Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer


Tel: +44 (0)1865 783 000


Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton




Tel: +44 (0)20 3709 5700


Notes for editors


About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange